Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco

[1]  M. Abrar,et al.  Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study. , 2016, Leukemia research.

[2]  U. Athale,et al.  Favorable Risk Group Acute Myeloid Leukemia in Children and Young Adult Treated in Uniform Protocol in Casablanca, Morocco. a Preliminary Analysis , 2015 .

[3]  M. Ozcan,et al.  Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients , 2015, Journal of clinical medicine.

[4]  S. Raimondi,et al.  Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Meshinchi,et al.  Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients , 2013, Cancer.

[6]  S. Rutella,et al.  Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. , 2013, Blood.

[7]  J. Rubnitz,et al.  Childhood acute myeloid leukaemia , 2012, British journal of haematology.

[8]  D. Johnston,et al.  Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. , 2012, Blood.

[9]  J. Rubnitz.  How I treat pediatric acute myeloid leukemia. , 2012, Blood.

[10]  S. Raimondi,et al.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia , 2012, Cancer.

[11]  K. Wheatley,et al.  Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial , 2011, British journal of haematology.

[12]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[13]  R. Hanada,et al.  Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Schlenk,et al.  Significance of age in acute myeloid leukemia patients younger than 30 years , 2008, Cancer.

[15]  S. Feig,et al.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.

[16]  D. Reinhardt,et al.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Hills,et al.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.

[18]  K. Wheatley,et al.  Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. , 2001, Blood.

[19]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.

[20]  J. Harbott,et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.